Knight Therapeutics Inc. has seen a notable shift in its stock performance this week amidst company news.
Knight Therapeutics Inc. (GUD.TO) has experienced a 1D decline of 0.86% and a weekly drop of 6.18%. The stock closed at C$9.50, reflecting a strong year-to-date performance of 56.68%. This week's price action is influenced by recent company announcements regarding their upcoming earnings call.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$917.00M
P/E
155.7x
52W high
$10.17
52W low
$5.66
1W change
-6.18%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 6.1% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+6.1% Upside
Current Price
C$9.26
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.8%
Annualized
90-Day Vol
30.1%
Annualized
Trend (90d)
+26.7%
Annualized drift
90d Mean
C$10.19
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.56 | C$8.80 – C$10.38 |
| 60 trading days | C$9.87 | C$8.78 – C$11.08 |
| 90 trading days | C$10.19 | C$8.83 – C$11.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Knight's upcoming earnings call and monitor the stock's technical indicators, particularly given its recent price movements and trading volume.
Knight Therapeutics Stock Closes at C$9.50
The stock has traded significantly above its 200-day moving average of C$7.21, indicating strong momentum despite recent volatility.
Bull case
Knight Therapeutics has shown impressive year-to-date growth of 56.68%, which suggests strong underlying business momentum. With a market cap of C$916.99 million and a noticeable increase in trading volume, there appears to be investor interest in the upcoming earnings results that could shed light on the company's performance.
Bear case
The stock's recent decline of 6.18% this week, combined with a high P/E ratio of 155.67, raises concerns about its valuation and the sustainability of its growth. Additionally, the low profit margin of 1.1% and ROE of 0.7% indicate potential challenges in profitability.
This Week's Price Action
Knight Therapeutics Inc. has experienced a slight pullback in its stock price, closing at C$9.50, down 0.86% for the day and 6.18% for the week. Despite this recent decline, the stock has seen a year-to-date gain of 56.68%, indicating strong overall performance.
Advertisement
Company News
Recently, Knight Therapeutics announced a conference call scheduled for July 30, 2026, to discuss its second-quarter results. This upcoming event has likely contributed to the current interest and volatility in the stock, as investors prepare for insights into the company's performance metrics.
Technical Picture
From a technical perspective, Knight Therapeutics is trading above its 50-day moving average of C$9.34 by 1.8% and significantly above its 200-day moving average of C$7.21 by 31.8%. The stock has a 52-week range of C$5.66 to C$10.17, indicating it is currently trading at 85% of its 52-week high. The beta of 0.05 suggests that the stock is less volatile compared to the overall market.
Trading Volume Insights
The latest trading volume for Knight Therapeutics was 222,165 shares, which is 1.87 times the 20-day average volume of 98,259 shares. This increase in volume indicates heightened interest from investors, which could be a response to the upcoming earnings call.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
